FDA Approves Two New Indications for Merck’s KEYTRUDA® (pembrolizumab)
Go back to FDA Approves Two New Indications for Merck’s KEYTRUDA® (pembrolizumab)| Merck & Co. (NYSE: MRK) | Delayed: 148.69 -0.09 (0.06%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $148.78 | 52 Week High | $65.46 | |||
| Open | $147.65 | 52 Week Low | $47.97 | |||
| Day High | $149.19 | P/E | 101.15 | |||
| Day Low | $146.28 | EPS | $1.47 | |||
| Volume | 7,612,887 | |||||
